<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292798</url>
  </required_header>
  <id_info>
    <org_study_id>FVF4978s</org_study_id>
    <nct_id>NCT01292798</nct_id>
  </id_info>
  <brief_title>Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab</brief_title>
  <acronym>REEF</acronym>
  <official_title>Open Label, Phase I/II, Residual Edema Evaluation With 0.5mg and 2.0mg Ranibizumab Formulations (REEF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Retina Consultants</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>California Retina Consultants</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase I/II study of intravitreally administered ranibizumab either
      0.5-mg and/or 2.0-mg in subjects with clinical, angiographic, and ocular coherence tomography
      (OCT) evidence of diabetic retinopathy with associated diabetic macular edema following
      bevacizumab therapy. Thirty patients will be enrolled in this study.

      Consented, enrolled subjects will receive multiple open-label intravitreal injections of 0.5
      mg ranibizumab administered every 30 days (±7 days) for 3 injections during the mandatory
      treatment phase (Day 0, Month 1, and Month 2).

      Subjects with complete resolution of diabetic macular edema after 3 intravitreal injections
      of 0.5 mg ranibizumab will be treated as necessary with 0.5 mg ranibizumab to treat recurrent
      macular edema for an additional 9 months (12 months from Day 0). The intent is to administer
      additional ranibizumab treatment if there is evidence of disease activity documented on OCT
      (e.g., intra-retinal fluid, subretinal fluid and/or cystic changes).

      Subjects with residual diabetic macular edema following 3 intravitreal injections of 0.5 mg
      ranibizumab will be receive 3 intravitreal injections of 2.0 mg ranibizumab administered
      every 30 days (±7 days) for 3 injections at the Month 3, Month 4, and Month 5 study visits.

      Beginning at the Month 6 study visit, subjects with complete resolution of diabetic macular
      edema following 3 intravitreal injections of 2.0 mg ranibizumab will treated as necessary
      with 2.0 mg ranibizumab injections only to treat recurrent macular edema for an additional 6
      months (12 months from Day 0).

      Subjects with residual diabetic macular edema following 3 consecutive intravitreal injections
      of 2.0 mg ranibizumab will be treated as necessary with 2.0 mg ranibizumab to treat
      persistent or recurrent macular edema for an additional 6 months (12 months from Day 0).
      Focal photocoagulation or intravitreal triamcinolone may be administered at the physician's
      discretion as an adjunct to ranibizumab injections beginning at Month 6 through Month 12 of
      the study.

      All subjects will make monthly visits for 12 months for evaluation of safety and efficacy.
      All subjects will have their first injection of ranibizumab on Day 0 and undergo a safety
      visit one week (±2 days) after the first injection. At subsequent visits, the subject will
      have a safety evaluation at the monthly scheduled follow-up visit prior to any intravitreal
      injection. Subjects will be contacted by the site personnel 1-2 days after each injection to
      elicit reports of decreased vision or pain or unusual new ocular symptoms in the study eye.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Mean Change in Visual Acuity Scores at Month 6 Compared to Baseline</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>To determine the mean change in the best-corrected visual acuity on an ETDRS visual acuity chart at a starting distance of 4 meters from baseline to 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in 1-mm Central Subfield (CST) Thickness as Measured by OCT at Month 6 Compared to Baseline</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>To determine the mean change in central 1-mm subfield thickness as measured by spectral-domain OCT from baseline to 6 months .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative Assessment of Diabetic Macular Edema (DME)</measure>
    <time_frame>Baeline and 6 months</time_frame>
    <description>To compare the percentage of subjects with compete or partial/no resolution of diabetic macular edema in response to the ranibizumab 0.5 and 2.0 mg doses.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>0.5mg and 2.0mgRanibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three consecutive intravitreal ranibizumab 0.5mg injections followed by three consecutive intravitreal ranibizumab 2.0mg injections if specific criteria is met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally</description>
    <arm_group_label>0.5mg and 2.0mgRanibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age &gt; 18 years

          -  Diagnosis of diabetes mellitus (type 1 or 2)Any one of the following will be
             considered to be sufficient evidence that diabetes is present:Current regular use of
             insulin for treatment of diabetes or current regular use of oral anti-hyperglycemia
             agent for the treatment of diabetes

          -  Clinical evidence of retinal thickening due to macular edema involving the center of
             the macula, associated with diabetic retinopathy.

          -  Previous history of two consecutive intravitreal bevacizumab injections for the
             treatment of diabetic macular edema with documented incomplete resolution of central
             subfield thickening by OCT (consecutive injections administered &lt; 7 weeks apart and
             within the past 12 months).

          -  Central diabetic macular edema present on clinical examination and OCT testing with
             central 1mm subfield thickness greater than 300 microns as measured on SD-OCT.

          -  Visual acuity score greater than or equal to 19 letters (20/400) and less than or
             equal to 73 letters (20/40) by the ETDRS visual acuity protocol.

          -  Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT
             testing and retinal photography

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women
             not using adequate contraception.

          -  Participation in another ocular investigation or trial simultaneously

          -  Blood pressure &gt; 180/110 (systolic above 180 OR diastolic above 110)

          -  Any condition that, in the opinion of the investigator, would preclude participation
             in the study (e.g. chronic alcoholism, drug abuse)

          -  Evidence of vitreoretinal interface abnormality after ocular exam or OCT that may be
             contributing to the macular edema

          -  An eye that, in the investigator's opinion, has no chance of improving in visual
             acuity following resolution of macular edema (e.g. presence of subretinal fibrosis or
             geographic atrophy)

          -  Presence of another ocular condition that may affect the visual acuity or macular
             edema during the course of the study (e.g. AMD, uveitis, Irvine-Gas)

          -  Evidence of neovascularization of the iris or retina

          -  Evidence of central atrophy or fibrosis in the study eye

          -  Presence of substantial cataract, one that might decrease the vision by 3 or more
             lines of vision at sometime during the study.

          -  History of vitreous surgery in the study eye

          -  History of cataract surgery within 6 months of enrollment.

          -  History of YAG capsulotomy within 2 months of enrollment.

          -  Visual acuity &lt;20/400 in the fellow eye

          -  Uncontrolled glaucoma (pressure &gt;30) despite treatment with glaucoma medications.

          -  History of cerebral vascular accident or myocardial infarction within 3 months prior
             to Day 0.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dante Pieramici, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Retina Consultants</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Institute of Hawai'i</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>69815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <results_first_submitted>January 27, 2016</results_first_submitted>
  <results_first_submitted_qc>March 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2016</results_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Macula</keyword>
  <keyword>Edema</keyword>
  <keyword>Retina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2.0 mg Ranibizumab</title>
          <description>Subjects who presented with persistent DME at month 3 following 3 months of monthly 0.5 mg ranibizumab injections received 3 monthly injections of 2.0 mg Ranibizumab.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Persistent DME After 3 Months</title>
              <participants_list>
                <participants group_id="P1" count="29">Subjects with persistent DME after 3 monthly injections of 0.5 mg of ranibizumab</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2.0 mg Ranibizumab</title>
          <description>Subjects who presented with persistent DME at month 3 following 3 months of monthly 0.5 mg ranibizumab injections received 3 monthly injections of 2.0 mg Ranibizumab.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Mean Change in Visual Acuity Scores at Month 6 Compared to Baseline</title>
        <description>To determine the mean change in the best-corrected visual acuity on an ETDRS visual acuity chart at a starting distance of 4 meters from baseline to 6 months.</description>
        <time_frame>baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.5mg and 2.0mgRanibizumab</title>
            <description>Three consecutive intravitreal ranibizumab 0.5mg injections followed by three consecutive intravitreal ranibizumab 2.0mg injections if specific criteria is met.
Ranibizumab: 0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change in Visual Acuity Scores at Month 6 Compared to Baseline</title>
          <description>To determine the mean change in the best-corrected visual acuity on an ETDRS visual acuity chart at a starting distance of 4 meters from baseline to 6 months.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in 1-mm Central Subfield (CST) Thickness as Measured by OCT at Month 6 Compared to Baseline</title>
        <description>To determine the mean change in central 1-mm subfield thickness as measured by spectral-domain OCT from baseline to 6 months .</description>
        <time_frame>baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.5mg and 2.0mgRanibizumab</title>
            <description>Three consecutive intravitreal ranibizumab 0.5mg injections followed by three consecutive intravitreal ranibizumab 2.0mg injections if specific criteria is met.
Ranibizumab: 0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in 1-mm Central Subfield (CST) Thickness as Measured by OCT at Month 6 Compared to Baseline</title>
          <description>To determine the mean change in central 1-mm subfield thickness as measured by spectral-domain OCT from baseline to 6 months .</description>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500.6" spread="129.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335.2" spread="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-165.4" spread="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Qualitative Assessment of Diabetic Macular Edema (DME)</title>
        <description>To compare the percentage of subjects with compete or partial/no resolution of diabetic macular edema in response to the ranibizumab 0.5 and 2.0 mg doses.</description>
        <time_frame>Baeline and 6 months</time_frame>
        <population>At 6 months, 18 out of the 43 subjects (42%) showed complete resolution of DME. 25 out of the 43 subjects (58%) showed partial or no resolution of DME at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg and 2.0mgRanibizumab</title>
            <description>Three consecutive intravitreal ranibizumab 0.5mg injections followed by three consecutive intravitreal ranibizumab 2.0mg injections if specific criteria is met.
Ranibizumab: 0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally</description>
          </group>
        </group_list>
        <measure>
          <title>Qualitative Assessment of Diabetic Macular Edema (DME)</title>
          <description>To compare the percentage of subjects with compete or partial/no resolution of diabetic macular edema in response to the ranibizumab 0.5 and 2.0 mg doses.</description>
          <population>At 6 months, 18 out of the 43 subjects (42%) showed complete resolution of DME. 25 out of the 43 subjects (58%) showed partial or no resolution of DME at 6 months.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>complete resolution</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>partial/no resolution</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>2.0 mg Ranibizumab</title>
          <description>Subjects who presented with persistent DME at month 3 following 3 months of monthly 0.5 mg ranibizumab injections received 3 monthly injections of 2.0 mg Ranibizumab.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hypoxic respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Research</name_or_title>
      <organization>California Retina Consultants</organization>
      <phone>8059631648 ext 3034</phone>
      <email>gabe@californiaretina.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

